Design and evaluation of highly selective HDAC6 inhibitors derived from the natural product tryptoline

View Full Paper

Ask AI

Bookmark

Authors

Discussion

This study demonstrates that compound 6a achieves 21-fold higher potency against HDAC6, indicating significant implications for cancer treatment.

Compound 6a shows 21-fold higher potency against HDAC6 compared to HDAC1, highlighting its selectivity.
In lung cancer cells, a low concentration of compound 6a significantly enhances α-tubulin acetylation, indicating effective inhibition.
Molecular docking reveals crucial interactions that support the strong and selective binding of compound 6a to the HDAC6 active site.
Selective HDAC6 inhibitors like compound 6a could lead to safer cancer therapies by minimizing the adverse effects of nonselective options.

Ali et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This study demonstrates that compound 6a achieves 21-fold higher potency against HDAC6, indicating significant implications for cancer treatment.